1. Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18.
- Author
-
Bogaards, Johannes A, van der Weele, Pascal, Woestenberg, Petra J, Benthem, Birgit H B van, King, Audrey J, and van Benthem, Birgit H B
- Subjects
- *
PAPILLOMAVIRUSES , *VACCINE effectiveness , *VACCINES , *DISTANCES , *COMPARATIVE studies , *BIOLOGICAL evolution , *IMMUNITY , *RESEARCH methodology , *MEDICAL cooperation , *PAP test , *PAPILLOMAVIRUS diseases , *POLYMERASE chain reaction , *PROTEINS , *RESEARCH , *HUMAN papillomavirus vaccines , *EVALUATION research , *TREATMENT effectiveness , *CROSS-sectional method , *GENOTYPES - Abstract
To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF